Jesus G Berdeja

Summary

Affiliation: Loma Linda University
Country: USA

Publications

  1. ncbi Immunotherapy of lymphoma: update and review of the literature
    Jesus G Berdeja
    Loma Linda University and Medical Center, Department of Medicine, California 92354, USA
    Curr Opin Oncol 15:363-70. 2003
  2. ncbi Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab
    Jesus G Berdeja
    Division of Hematology and Oncology, Loma Linda University Medical Center, Loma Linda, California 92354, USA
    Clin Cancer Res 13:2392-9. 2007

Collaborators

Detail Information

Publications2

  1. ncbi Immunotherapy of lymphoma: update and review of the literature
    Jesus G Berdeja
    Loma Linda University and Medical Center, Department of Medicine, California 92354, USA
    Curr Opin Oncol 15:363-70. 2003
    ..This review will summarize the state of the art of this burgeoning therapy...
  2. ncbi Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab
    Jesus G Berdeja
    Division of Hematology and Oncology, Loma Linda University Medical Center, Loma Linda, California 92354, USA
    Clin Cancer Res 13:2392-9. 2007
    ..A pilot trial of rituximab and LAK cells in patients with rituximab-refractory CD20+ lymphoma was conducted to evaluate this approach...